These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 10215754)
21. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Baner K; Benet LZ; Sewing KF; Christians U J Pharmacol Exp Ther; 1999 Oct; 291(1):131-9. PubMed ID: 10490896 [TBL] [Abstract][Full Text] [Related]
22. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Andrus MR Pharmacotherapy; 2004 Feb; 24(2):285-90. PubMed ID: 14998226 [TBL] [Abstract][Full Text] [Related]
23. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Wong WW; Tan MM; Xia Z; Dimitroulakos J; Minden MD; Penn LZ Clin Cancer Res; 2001 Jul; 7(7):2067-75. PubMed ID: 11448925 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Neuvonen PJ; Backman JT; Niemi M Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955 [TBL] [Abstract][Full Text] [Related]
26. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Clarke TA; Waskell LA Drug Metab Dispos; 2003 Jan; 31(1):53-9. PubMed ID: 12485953 [TBL] [Abstract][Full Text] [Related]
27. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. Turner NA; Midgley L; O'Regan DJ; Porter KE J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315 [TBL] [Abstract][Full Text] [Related]
28. Sex difference in inhibition of in vitro mexazolam metabolism by various 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in rat liver microsomes. Ishigami M; Takasaki W; Ikeda T; Komai T; Ito K; Sugiyama Y Drug Metab Dispos; 2002 Aug; 30(8):904-10. PubMed ID: 12124308 [TBL] [Abstract][Full Text] [Related]
29. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Benet LZ; Sewing KF; Christians U Drug Metab Dispos; 1999 Feb; 27(2):173-9. PubMed ID: 9929499 [TBL] [Abstract][Full Text] [Related]
30. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. Zahno A; Brecht K; Bodmer M; Bur D; Tsakiris DA; Krähenbühl S Br J Pharmacol; 2010 Sep; 161(2):393-404. PubMed ID: 20735423 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Williams D; Feely J Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392 [TBL] [Abstract][Full Text] [Related]
32. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Neuvonen PJ; Niemi M; Backman JT Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259 [TBL] [Abstract][Full Text] [Related]
33. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Igel M; Sudhop T; von Bergmann K Eur J Clin Pharmacol; 2001 Aug; 57(5):357-64. PubMed ID: 11599653 [TBL] [Abstract][Full Text] [Related]
34. CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control. Kitzmiller JP; Sullivan DM; Phelps MA; Wang D; Sadee W Drug Metabol Drug Interact; 2013; 28(1):59-63. PubMed ID: 23314529 [TBL] [Abstract][Full Text] [Related]
35. Interaction between fibrates and statins--metabolic interactions with gemfibrozil. Fujino H; Yamada I; Shimada S; Hirano M; Tsunenari Y; Kojima J Drug Metabol Drug Interact; 2003; 19(3):161-76. PubMed ID: 14682608 [TBL] [Abstract][Full Text] [Related]
36. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Yang SH; Choi JS; Choi DH Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429 [TBL] [Abstract][Full Text] [Related]
37. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Eagling VA; Tjia JF; Back DJ Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822 [TBL] [Abstract][Full Text] [Related]
38. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Prueksaritanont T; Subramanian R; Fang X; Ma B; Qiu Y; Lin JH; Pearson PG; Baillie TA Drug Metab Dispos; 2002 May; 30(5):505-12. PubMed ID: 11950779 [TBL] [Abstract][Full Text] [Related]
39. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms. Renwick AB; Surry D; Price RJ; Lake BG; Evans DC Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104 [TBL] [Abstract][Full Text] [Related]
40. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]